Portfolio: Life Sciences
Atritech
An innovator in stroke prevention for patients with atrial fibrillation, Atritech, Inc. is a clinical stage company based in Plymouth, Minnesota. The company's WATCHMAN® device is designed to prevent strokes by keeping harmful sized blood clots from entering a patient's blood stream.
Avedro, Inc.
Avedro, Inc. is an early-stage medical device company commercializing therapeutic microwave technology, originally conceived and developed at Dartmouth College. The company is developing a non-incisional refractive surgery procedure capable of treating myopia and offering a less invasive alternative to laser vision correction (LASIK).
CoAxia
CoAxia™ is a development-stage company in clinical trials with an innovative, catheter-based therapy for the treatment of ischemic stroke and vasospasm. The company has developed 510(k)-cleared and CE-marked catheters, called FloControl™ and NeuroFlo™. The catheters use saline-filled balloons to partially restrict blood flow in the descending aorta. In the case of the NeuroFlo device, the procedure diverts cardiac output to the brain, causing an immediate increase in cerebral perfusion, an improvement in neurological symptoms and with little-to-no increase in arterial blood pressure.
Entrigue Surgical, Inc.
Founded in 2007, ENTrigue Surgical is an early commercial stage company that is developing several product platforms for the relatively underserved Ears, Nose, & Throat market. Among ENTrigue's first commercialized products are a line of articulating instruments; a septal stapling system utilizing resorbable staples; and a line of resorbable suture and tissue repair products based on a new class of polymers with a profile of strength, flexibility, and soft tissue compatibility that is unique when compared to existing resorbable polymers.
iScience Interventional
iScience Interventional™ pioneered and leads in the discovery and development of fiber-optic guided micro-catheter and imaging platforms that enable ophthalmologists to deliver site-specific treatments in the eye. The iTRACK™ 250 & 370 ophthalmic micro-catheters, combine with the iLumin™ fiber optic light source and iUltraSound™ imaging system to establish the company’s foundational armamentarium needed to facilitate interventional treatment of the ophthalmic patient; all via anatomically-compliant routes of access.
Locus Pharmaceuticals, Inc.
Locus Pharmaceuticals is a pharmaceutical company focused on developing novel, small molecule therapeutics to address major unmet medical needs. Locus utilizes powerful and proprietary computational technologies running on Linux-based supercomputer clusters to simultaneously identify relevant binding sites on protein disease targets and rapidly generate novel, small molecules that bind specifically to those protein sites. In contrast to other computational approaches, the Locus technology requires only a high-resolution, 3-dimensional structure of the target protein to implement its drug discovery process. Presently, Locus Pharmaceuticals is synthesizing and testing novel drug candidates for the treatment of debilitating and life-threatening human diseases, including HIV/AIDS, cancer, arthritis and inflammation.
OptiScan Biomedical Corporation
OptiScan is a development stage company with a proprietary method of measuring blood glucose using an optical approach. Blood glucose monitoring for diabetes patients today is a $3+ billion business involving painful, inconvenient finger sticks. OptiScan intends to create the next generation of blood glucose meters that will deliver a new standard of clinically relevant accuracy.
Proteon Therapeutics Inc.
Proteon Therapeutics is a biopharmaceutical company developing PRT-201, a novel human recombinant protein that permanently dilates segments of blood vessels, blocks vasospasm, and reduces the formation of vascular scarring. This unique combination of features is crucial for improving both the immediate and long-term success of hemodialysis access, bypass graft and angioplasty procedures.
ROX Medical
ROX Medical is taking a completely new approach to treating chronic obstructive pulmonary disease. ROX's minimally invasive device has the potential to treat many more patients than current lung modification strategies.
Trius Therapeutics
Trius Therapeutics is discovering and developing innovative antibacterial drugs for the treatment of life-threatening infections. The company’s lead product candidate, TR-701 is a novel oral and IV oxazolidinone antibiotic with potent activity against Gram positive bacterial pathogens. Trius’ pipeline includes three additional structure-based drug design programs directed against novel antibacterial targets. The most advanced program has reached animal efficacy testing.
XLumena
XLumena is an endosurgery company developing novel medical devices that enable translumenal EUS therapy. Endoscopic Ultrasound (EUS) is an established high resolution imaging method that allows the physician to see outside the GI lumen. When existing EUS is used with XLumena devices, the physician can operate on neighboring organs with the advantage of simple, safe and effective procedures.
